TLR4 and Parkinson disease: Recently, it has been reported that orally administrated 10 g/kg/day CDG in PD mouse models can ameliorate MPTP-induced gut microbial dysbiosis, inflammatory responses in the CNS and colon via blocking the TLR4/NF-κB pathway, which in turn protected the intestinal barrier responses [31].